Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
The Journal of Allergy and Clinical Immunology|August 17, 2018
Development and characterization of DNAzyme candidates demonstrating significant efficiency against human rhinovirusesDaniel P Potaczek, Sebastian D Unger, Nan Zhang, et al.
The Journal of Allergy and Clinical Immunology|July 5, 2016
Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammationHolger Garn, Sabine Bahn, Bernhard T Baune, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2022
Single-cell RNA sequencing uncovers the nuclear decoy lincRNA PIRAT as a regulator of systemic monocyte immunity during COVID-19Marina Aznaourova, Nils Schmerer, Harshavardhan Janga, et al.
The Journal of Investigative Dermatology|September 17, 2023
Type 2 T-Cell Responses against Distinct Epitopes of the Desmoglein 3 Ectodomain in Pemphigus VulgarisDario Didona, Luca Scarsella, Christoph Hudemann, et al.
Cellular & Molecular Immunology|June 28, 2024
BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cellsBilal Alashkar Alhamwe, Viviane Ponath, Fahd Alhamdan, et al.
Allergy|September 15, 2019
EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthmaCarina Venter, Matthew Greenhawt, Rosan W Meyer, et al.
Allergy|April 30, 2019
EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitisCarina Venter, Rosan W Meyer, Bright I Nwaru, et al.
The British Journal of Dermatology|August 12, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigusDario Didona, Christoph Hudemann, Holger Garn, et al.
Leukemia|January 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)Andreas Burchert, Franck E Nicolini, Philipp le Coutre, et al.
Pageof 12